#ESMO26 The prespecified HRQoL analysis from phase III KEYNOTE-B15/EV-304 was presented:
🔹 Efficacy: EV+P improved EFS (HR 0.53) and OS (HR 0.65) vs neoadjuvant gemcitabine/cisplatin.
🔹 Global QoL at postsurgery week 42: −1.58 vs −2.43 points, with no meaningful between-group difference.
🔹 Physical function: −5.42 vs −6.28 points; role function: −9.56 vs −9.35 points.
🔹 Sexual function: The largest and most persistent deterioration (−15.13 vs −14.82 points), regardless of treatment.
@UroToday @myESMO
10 views · 0 likes · 0 reposts · 0 replies
ctDNA analysis of the Phase 3 KEYNOTE-B15 trial: neoadjuvant and adjuvant (neoadj-adj) enfortumab vedotin (EV) + pembrolizumab (pembro) for participants (pts) with muscle-invasive bladder cancer (MIBC) who are eligible for cisplatin
https://esmocongress.esmo.org- **标题 / Title：** Perioperative Enfortumab Vedotin (EV) Plus Pembrolizumab (MK-3475) Versus Neoadjuvant Chemotherapy for Cisplatin-Eligible Muscle Invasive Bladder Cancer (MIBC) (MK-3475-B15/ KEYNOTE-B15 / EV-304)
https://esmocongress.esmo.orgSource: Julian Chavarriaga · x.com